JAK Inhibitor Shows Promise in Severe Type of Sclerosis
(MedPage Today) -- The Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) eased the severe inflammatory and dermatologic symptoms of disabling pansclerotic morphea (DPM), an initial clinical series showed.
After a series of basic science and in...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news